Spruce Street Capital »

Enliven Therapeutics shares owned by Spruce Street Capital

Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by Spruce Street Capital from 13F filings

Historical chart of Spruce Street Capital investment in Enliven Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Enliven Therapeutics held by Spruce Street Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Enliven Therapeutics by Spruce Street Capital

Quarter filed Position value Share count Share price at filing
2026-06-30 $17M 329k 50.75

More positions owned by Spruce Street Capital

Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA)
Relay Therapeutics (RLAY)
Lb Pharmaceuticals Com Shs (LBRX)
Relmada Therapeutics (RLMD)
Alto Neuroscience Com Shs (ANRO)
Dianthus Therapeutics (DNTH)
Alkermes SHS (ALKS)
Savara (SVRA)
Vaxcyte (PCVX)
Enliven Therapeutics (ELVN)
Enanta Pharmaceuticals (ENTA)
Perspective Therapeutics Com New (CATX)
Inflarx Nv (IFRX)
Surrozen Com New (SRZN)
Alumis (ALMS)

View all positions for Spruce Street Capital

Top funds holding Enliven Therapeutics

OrbiMed Advisors
FMR
Polar Capital Holdings
BlackRock
Commodore Capital
Vestal Point Capital
Vanguard Capital Management
Bellevue Group
Citadel Advisors
Fairmount Funds Management
VR Adviser
Novo A/S
Pictet Asset Management Holding SA
State Street Corporation
Geode Capital Management

View all funds holding Enliven Therapeutics